What’s up everyone. Thanks for tuning into Money Talkz. We’ve taken a break here at Money Talk Sundayz to spend time with the family. This will be the last episode for 2021 so I hope you all had a merry Christmas and have a safe and enjoyable New Year’s Eve.

I wanted to look back at some of the events this year that spurred Money Talk Sundayz as well as look back at some of the predictions that were made and how they panned out. At first, I was considering doing a top 10 but I don’t want to drag this out too long, so we’ll go with a top 5 for the year. It’ll be a top 5 from the podcast streaming and the top 5 from YouTube. Do expect some overlap and some topics to come up more than once on both platforms. We’re getting the word out!

I started the podcast at the beginning of May but the first post to YouTube was May 16th when we uploaded MTS Episode 2 broken into 3 parts: Part 1 - Dogecoin Isn’t Going Anywhere, Part 2 – Cryptocurrency, and Part 3 – Plays of the Week. Obviously, Doge is not where it once was earlier this year and has struggled to recover.

Every week since the beginning of June at least one episode was posted on YT each week bringing you what we thought the market was doing and plays we were making or suggesting be made. It was a slow grind building the channel and we’re still growing but things didn’t really start making moves until Vaxart came on the radar. For this reason, Vaxart ranks number at the top of our favorite episodes/stocks/coverage etc. You the viewers were just as eager to see VXRT make a breakthrough as I was. For the record I hold more shares of Vaxart than any other stock right now. And I continue to hold and every now and then grab up a few more.

When I run the stats for the lifetime of the channel, our Vaxart coverage appears 8 times in the top 10 most viewed videos for this period. You guys made this happen. The two other stocks that appear in the top 10 are “MMAT Price Jumps on Short Squeeze” and Jaguar Health Inc. (JAGX) Is It a Good Time to Buy?”.

Runner ups go to Atossa Therapeutics and SNDL, both of which I’ve only covered once but made money prior to the inception of the podcast.

Over on the podcast streaming between Apple and Spotify and a host of other streaming services, the numbers are a somewhat different. Taking the top spot was our “BBIG Moon Landing; Vinco Ventures Squeeze on the Way” followed by our “VXRT vs ORMP: Vaxart vs Oramed” episode. When it comes to the streaming services’ top 10 Vaxart is on the list 3 times as opposed to 8 on YT.

Our Ocugen and MARK put episodes were timed perfectly allowing us to secure profits on the hype that was being blown up peoples’ rears. If you timed it along with us congrats and give yourselves a pat on the back.

One big thing that sticks out looking back though is the price prediction for Bitcoin back at the beginning of the year. Experts were predicting that Bitcoin would reach $100K by the end of the year. I was skeptical and voiced it but there were moments that I thought it would do it. But alas, on 12/28/2021 Bitcoin is down currently priced at $47,482.16. And like I always say as Bitcoin goes so does the rest of the crypto arena.

In summary, I just want to thank all of you for subscribing, sharing, liking, commenting and more. 2022 we plan to come back in full force with some plays, some news coverage, and more transparency and chronicling of our journey to $100K. Kyng V will be back. He keeps telling me that so I’m telling you guys that. Investment Bros is still in effect, and we still want you to join the marathon too! Subscribe! Let’s make this money.

Lucid Motors is a buy right now. Why? It’s set to make some big waves in the electric vehicle market. Buyers and investors are already lining up and making reservations. Production and sales around one hundred grand equate to a minimum of 12 billi in revenue potential. The stock prices have fallen in recent weeks to no fault of the company. Attribute it to people taking profits in a soaring company. Now’s your turn to get in and get a piece of the pie. Let’s talk lucid about LCID.

Welcome to Money Talk Sundayz. I’m your investment bro Stevie Bee. Thanks for tuning in. Run that like, share, and subscribe. Let’s pump the YouTube algorithm and squeeze these numbers.

Lucid Motors is an auto manufacturer in the electric vehicle market. They place an exceptionally high priority on efficiency ensuring that their cars maximize their use of the world’s resources sustainably. They seek materials from the most responsible suppliers — with a focus on sustainable standards and the potential for recyclability. Their band new factory is the first purpose-built EV facility in North America — designed expressly for the needs of the consumer and environmentalist alike.

Lucid Motors’ Lucid Air has been named Motor Trend’s Car of the Year for 2022.

Reservations for the Lucid Air, Lucid Motors' first attempt at producing an electric vehicle, are increasing.

Top 3 reasons why LCID is a buy right now:

1. The company has already begun deliveries of their cars to customers while reservations for vehicles are rising.

2. The Lucid Air range of 520 miles is unparalleled and unmatched in the industry. Even by Tesla. No company comes close to this range rating.

3. Production of the Air Sedan has just commenced. LCID will be revealing more details about other new models in the coming weeks.

There are many EV companies that showcase their prototypes and pre-production models, but only a few can show a finished product that is selling. This is where Lucid Motors distinguishes itself in an increasingly crowded field. In October, the electric-vehicle company began making customer deliveries to reservation holders, and reservations are increasing.

The company is currently sitting on 17K reservations for the Air Sedan which is up from 13K reservations in the previous reservation status. With their new facility in Arizona the company is looking to scale up to around 34K cars in the first phase of their build up. At this rate Lucid is on the money to exhaust half of its production capacity just off reservations.

In September, the Lucid Air Dream Edition sedan received the highest EV category range rating from the EPA, 520 miles, beating the nearest competitor by a solid 100 miles. No other EV product on the market comes close to Lucid Motors, which, let's face it, is a pretty good selling point for customers looking to contribute to the EV revolution by purchasing an electric vehicle with their hard-earned money. As a result, the Lucid Air sedan and its various special editions should prove to be best-selling models, resulting in a significant increase in sales once Lucid Motors reaches mass production capacity.

Lucid Motors is currently on track to produce and sell only one primary product: The Lucid Air sedan. But, behind the scenes, the electric-vehicle manufacturer is hard at work on its second project, which will see the introduction of the Gravity luxury SUV. The SUV from Lucid Motors is still in the design phase, and few details have been revealed so far, other than the fact that the new electric-vehicle will be available in 2023.

Just as the title of the episode indicates, Vaxart stock is on the rise after breaking out of the pennant pattern it has been in for some time now. As I mentioned in previous episodes, VXRT’s share price has been getting squeezed between ever narrowing highs and lows for a while and over the last couple days has broken past resistance and is testing a new support level. Bag holders like you and I know that this break above resistance will let the stock to continue to push higher as volume continues to move into the stock. Ready to talk Vaxart? Let’s go.

Welcome to Money Talkz, the gems I drop between the weekly Money Talk Sundayz podcast. I’m your investment bro Stevie Bee. Special shout out to all the new subs. I appreciate all of you. You know the business, run that like, share, and subscribe. If you’re a VXRT holder you definitely want to sub. This is a special edition of our Vaxart Watch.

Let’s get it.

As you can see on the chart, VXRT is making moves and breaking past its resistance level. You know how they say today’s price is not tomorrow’s price? Well yesterday’s resistance is today’s support for Vaxart. Things are trending favorably and now is definitely a time to grab up more shares of Vaxart before you get priced out.

The stock is trading above both the 50-day moving average (which is the green line there) and the 200-day moving average (which is the blue line there), indicating sentiment in the stock looks to be turning bullish. Each of these moving averages may hold as a possible area of support in the future. The Relative Strength Index (RSI) has pushed higher the past few days and now sits at 62 on the indicator. What this means is that buying pressure is strongly outweighing the selling pressure in the stock.

Ignore the FUD (fear, uncertainty, doubt)!!!! Focus on the facts!!! Vaxart is a winner! Moderna CEO has already come out saying that the current vaccines out are less effective against the new Omicron Covid variant. Vaccine resistance could lead to more sickness and hospitalizations and prolong the pandemic, and his comments triggered selling in growth-exposed assets like oil, stocks, and the Australian dollar.

We are anticipating even higher lows for VXRT. Over the next several days expect to see above average trading volume for Vaxart stock. Barring some crazy news expect the stock to remain above the moving averages. Stay bullish bros nation!

In press news, Vaxart, Inc. announced that the company’s vice president, Sean Tucker, will attend and speak at the World Vaccine & Immunotherapy Congress West Coast 2021, being held today. As of this recording it hasn’t happened yet, but I will let Bros Nation know how it goes.

It’s part of an award-winning series of conferences and exhibitions that’s steadily rising to become the world’s largest and most established vaccination events. Vaxart’s CSO will discuss the company’s research program for an oral candidate for the COVID-19 vaccine in the form of tablets. The medicine that needs to be swallowed against coronavirus is the only oral vaccine of its kind against COVID-19, which has immunological potential, which is confirmed. And this is the only vaccine that has been conducting Phase 2 clinical trials since October 2021.

If you haven’t done so, as a shareholder it is in your best interest to go to Vaxart.com and subscribe to their alerts.

It is the day after Thanksgiving and one of the first things to hit my alerts this morning was the news of a new Covid variant giving everyone pause. Rightfully so, the market’s response to this news was as expected so I had to check on my favorite biotech stock, VXRT. It was already up in premarket and closed the day up a little over 5%. in aftermarket it went up an additional 1% making me several hundred dollars on the day. If you tuned into the Winter is Coming episode on Vaxart you already know that this bump is indicative of what’s to come. In the last VXRT episode covering the squeeze pattern the stock is experiencing I said the stage is set for it to breakout. Are we on the verge of the next bull run? Let’s look at a couple of factors and you be the judge.

Welcome to Money Talk Sundayz. I’m your investment bro Stevie Bee with another installment of our Vaxart Watch. Run that like button. Subscribe and share if you’re feeling even more bullish on VXRT.

Here’s a bit of news I just found out and I haven’t heard or seen much chatter about it. We all know that Vaxart is conducting phase 2 trials of their covid vaccine tablet. What many of you may not have heard however is that the study will also be assessing the viability of the vaccine candidate as a “booster” for those who’ve received the injectable vaccine. Reports stated that the efficacy of the injectable vaccine wanes over time thus the need for a vaccine booster. The company’s Phase II trial is investigating its vaccine as a booster dose in people who have previously received an mRNA vaccine in their primary series. With the need for boosters comes more time for Vaxart to complete their phase 2 study.

The problem with the regular booster shots come from familiarity. Reports indicated adenovirus-vectored Covid-19 vaccines may face efficacy issues if they are used again as boosters because the immune system would be able to recognize and debilitate the vector.

Now obviously the convenience of the pill trumps many concerns and gives VXRT an advantage. Some are not needing a cold chain protocol, as well as doing away with needles, syringes, and vials. Also, as Vaxart chief scientific officer Sean Tucker points out, the vaccine has the additional potential benefit of sidestepping unwanted antivector responses as expected with other adenovirus-vectored vaccines. Vaxart uses the adenovirus type 5 (Ad5) as its vector. In addition, there is preclinical data showing its oral vaccine could also prevent SARS-CoV-2 transmission to unvaccinated individuals.

Just a little over a month ago crap outlets like the Motley Fool were claiming that it was too little too late for Vaxart but here we are with covid spikes around the globe and a new variant starting to make its rounds. Markets are reeling and countries are back to implementing travel bans just as the holiday season is kicking off. Vaxart is in a prime space to carve out its own niche in the vaccine market. Vaxart’s oral vaccine is much more straightforward to investigate in a clinical trial than ones that require a needle and syringe.

So how is the pill supposed to work you may be wondering. Vaxart’s Covid-19 vaccine tablet has a coating that allows it to survive the low pH in the stomach. Once it reaches the lower small intestine, its adenovirus vectors are released to infect epithelial cells. Once the genetic code is delivered, the host cell manufactures the SARS-CoV-2 spike antigen, as well as a double-stranded hairpin turn adjuvant. Vaxart’s vaccine draws a stronger response in the lower small intestine potentially due to specific immune system cells in this region, as well as local digestive enzymes assisting with the response.

From the covid pill to the flu vaccine Vaxart is making a name for itself as a revolutionary disruptor in the vaccine industry. Phase 2 clinical trials began in the third quarter for VXRT’s oral vaccine candidate with an expected completion date of spring 2022. Results from the Phase II human influenza challenge trial showed that those who were given VXA-A1.1 were better at providing protection against viral shedding compared to the injected inactivated influenza vaccine (IIV). All this while stock prices show a squeeze at the end of a pattern. Will Vaxart blow past resistance or crash through support? Let’s find out.

Welcome to Money Talk Sundayz. I’m your Investment Bro Stevie Bee. I hope you enjoyed my last VXRT episode. Run that like share and subscribe button. Let’s get to it.

A new study shows that there might be a way to protect against influenza infection without needing to stir up antibody response. Scientists from Stanford University investigated the effectiveness of an oral tablet flu vaccine called VXA-A1.1 by Vaxart, which uses cellular correlates of protection. Results from the Phase II human influenza challenge trial showed that those who were given VXA-A1.1 were better at providing protection against viral shedding compared to the injected inactivated influenza vaccine (IIV).

Those who received VXA-A1.1 were found with plasmablasts and hemagglutinin (HA+)-specific cells that contributed to protection from viral shedding after 90 days. This was not seen in those who got IIV or a placebo. On day 8, those who were given the oral drug demonstrated T cell expressing markers that suggested enhanced mucosal tissue homing.

Details of the VXA-A1.1 study are published in Cell Host and Microbe.

On the Covid front, the company began the first Phase II trial of their investigational COVID-19 oral tablet vaccine and dosed the first participants. The whole data set from this investigation is expected to be accessible in Q1 2022, according to Vaxart.

Published results by Duke University show that the company’s COVID-19 vaccine candidate reduced airborne transmission of the SARS-CoV-2 virus in a preclinical animal model. Vaxart also improved its research and manufacturing capacity, allowing it to move forward with the production of the vaccine candidate.

CEO Andrei Floroiu stated, “Vaxart made significant progress this quarter toward its goal of developing a next-generation oral tablet COVID-19 vaccine. We have started our United States Phase II trial and anticipate beginning international trials in the near future. This is an important milestone, as our candidate is the only oral COVID-19 vaccine to progress to Phase II trials in the U.S.”

Vaxart founder and Chief Scientific Officer Dr. Sean Tucker said The progress we made in our vaccine research this quarter was significant. We already learned from an earlier human influenza challenge study that our oral flu vaccine candidate inhibited the shedding of viral RNA better than injectable vaccines. In addition, our published hamster study showed that our vaccine candidate could reduce transmission of SARS-CoV-2, even when there is an infection breakthrough in a vaccinated subject. The implications are significant because existing injected vaccines do not always protect against viral shedding and transmission to other people.”

Vaxart Inc. stock is now 23.64% up from its year-to-date (YTD) trading value. VXRT Stock saw the intraday high of $7.29 and lowest of $6.77 per share.

Compared to the average trading volume of 3.53M shares, VXRT reached a trading volume of 5943937 in the most recent trading day, which is why market watchdogs consider the stock to be active.

With this latest performance, VXRT shares gained by 2.32% in over the last four-week period, additionally plugging by 5.37% over the last 6 months – not to mention a rise of 23.86% in the past year of trading.

Brief Summary:

Part 1: An open label, dose and age escalation phase to evaluate the safety and immunogenicity of VXA-CoV2-1.1-S with a repeat-dose vaccination schedule in healthy adults aged 18 - 75 years old that are either vaccine naive or have received prior vaccination with an mRNA (messenger ribonucleic acid) vaccine for the prevention of COVID-19.

Part 2: This phase will assess the efficacy of prophylactic VXA-CoV2-1.1-S against confirmed COVID-19 occurring from 7 days after second dose with a repeat-dose vaccination schedule in healthy adults compared to placebo. Safety and immunogenicity of VXA-CoV2-1.1-S will also be evaluated in this phase.

As the weather gets cooler and winter approaches, doctors are predicting a spike in COVID-19 cases and more hospitalizations which could put emergency departments at risk of being overwhelmed again.

California has begun positioning equipment and locking in contracts with temporary health care workers in preparation for another possible winter surge of coronavirus cases, Gov. Gavin Newsom said Wednesday.

VXRT’s earning reports are in and currently in phase 2 of their clinical trials for their Covid vaccine pill. Vaxart also rose 46.73% from its 52-week low and is up 20.67% year to date. While Covid numbers in the US are trending south, the rest of the world is still being ravaged. Do you buy, sell, or hold? Are we still bullish or are we now bearish? Let’s break it down in today’s episode of Money Talk Sundayz.

Thanks for tuning in to Money Talk Sundayz. I’m your investment Bro Stevie Bee. It’s been a few weeks since I last covered Vaxart so today we’re going to circle back and see what’s up with our favorite oral vaccine candidate stock. Hit that like button on your way in and let’s get started.

During the recent session, Vaxart Inc. (NASDAQ:VXRT)’s traded shares were 1.68 million, with the beta value of the company hitting 0.24. At the last check today, the stock’s price was $6.57, reflecting an intraday loss of -4.64% or -$0.32. The 52-week high for the VXRT share is $24.90, that puts it down -279.0 from that peak though still a striking 46.73% gain since the share price plummeted to a 52-week low of $3.50. The company’s market capitalization is $887.57M, and the average trade volume was 4.52 million shares over the past three months.

Vaxart Inc. (VXRT) is currently still a recommended Buy from analysts.

Vaxart Inc. (VXRT) registered a -4.64% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -4.64% in intraday trading to $6.57 this Thursday, 11/04/21, hitting a weekly high. The stock’s 5-day price performance is -0.14%, and it has moved by -2.96% in 30 days. Based on these gigs, the overall price performance for the year is 34.57%.

Per the CEO, VXRT’s oral vaccine candidate “is the only oral COVID-19 vaccine to progress to Phase II trials in the U.S.”

Vaxart recently brought online its own GMP manufacturing facility and is now producing vaccines at two GMP plants. This has allowed the Company to manufacture all of the COVID-19 vaccine oral tablets for the clinical trials started and planned to start this year, and to begin manufacturing vaccines for its upcoming norovirus Phase II trials.

Vaxart scaled up its research, quality and manufacturing capabilities, increasing its R&D employee headcount by more than 35% during the quarter.

Vaxart named Dr. James F. Cummings as its Chief Medical Officer. Dr. Cummings is a board-certified infectious disease physician with extensive experience in vaccine, drug and diagnostics development, and will help guide the Company’s development of its vaccines.

I hate, rather deplore the term, meme stock. The connotation behind it in my opinion throws shade on actual stocks. Before “meme stocks” the black sheep of trading was penny stocks. Haters swore there was no money in penny stocks. From experience I can say that is not true. Since the GameStop and AMC craze earlier this year the media has adopted the term meme stock and the term isn’t going away. Hard to fight the corporate machine. Since we can’t shirk the side eye of trading meme stocks, we can certainly take control of the narrative and win trading these stocks. Here’s how.

Welcome to Money Talk Sundayz. I’m your Investment Bro Stevie Bee. Hit that like button on your way in. Let’s talk meme stocks.

I want to share with you 9 things to keep in mind when playing the meme stock game. If you keep these in mind you will undoubtedly acquire and maintain a winning portfolio and keep the money flowing in.

#1 Nano Hands.

When I say nano hands, think Iron Man. His hands are capable of a variety of different actions from shooting lasers, jet propulsion, to coming off entirely. With meme stocks, your hands must be able to adapt with any situation that may arise. Therefore, forget the Diamond Hands nonsense and secure your profits whenever possible. You can sell and should sell when you feel comfortable. Do not, I repeat do not be pressured into holding onto a stock longer than you are comfortable with. If your gut is telling you, it’s time to cut it loose, CUT IT LOOSE! If you let the opinions and actions of others intimidate or enrage you, you are in the wrong game. Life is too short to be bothered with someone else’s opinions. Get your money and move on.

#2 Risk Tolerance.

In other words, only trade what you can afford to lose. If you find yourself in a position where you must choose between paying your rent/mortgage or car note or any other base necessity for living and trading meme stocks, you’re doing it all wrong. Take care of your business. Yes there is big money to be made and can be made in minutes as we’ve seen with Digital World Acquisition Corp (DWAC), Phunware (PHUN) and more but there is just as much money to be lost in a matter of minutes. When trading meme stocks you must honestly ask yourself, are you ok with losing this money.

#3 Meme Stock Volatility.

Meme stocks tend to be very volatile. So much so, at any given moment brokerages will halt trading on them as we’ve seen many times this year. Meme stocks swing faster than Brangelina at a swingers’ convention. Meme stocks move fast because they are heavily shorted and have an emotional component that hooks people in on a gut level. Meme stocks are also mostly owned by retail traders, so institutions have a smaller impact on movements.

#4 Accept the Meme Stock Consequences.

Acknowledge the fact that these are meme stocks and along with assessing your risk tolerance know you’re playing a dangerous game. Indeed, with high risk comes big rewards but it can also go the other way. Accept this fact that you are chasing big payouts quickly. That is the cold hard facts.

#5 Kill FOMO.

You missed out? Get over it. Don’t let FOMO drive your decisions. Perfect example is MARK or Remark Holdings. We talked about it last week. I also did a follow up to it. If you haven’t seen it check those two episodes out. MARK had a huge breakout in premarket last week Monday only to crash and burn. You need to accept when you’ve missed the boat. If you open your platform and that stock you were watching is up 300% from yesterday… let it go. By the time your jump in is in the books everyone else is taking their profits and running leaving you holding the bag. There will ALWAYS be another stock to trade.

Remark did as expected albeit after a quick and short lived run up in pre-market Monday morning. On Sunday during the podcast I reported that it was trading at 2.86. By the next morning it was well into the $6 range. The perfect time to play the put option, just as I mentioned during that episode. Let’s discuss what exactly happened with MARK.

Welcome to Money Talk Sundayz. Thanks for tuning in. Hit that like button on your way in the door and lets get started.

MARK was the big question for Monday. Sources from all walks of life were swearing by this stock as the one. But the more in premarket it rose the more inevitable the pullback or correction. And the pullback game was strong. Within 48 hours of the last episode Mark was down from over $6 to dipping below $2.

Some of you asked what happened. Why did it fall so much? The answer is pretty simple, human emotion. This stock like so many others is viewed as a meme stock. Investors in meme stocks for the most part are in it for the short term gains. A run up like what happened Monday morning is exactly what investors are looking for. They cash in quick and fast while like many of you who weren’t already invested catch on too late and buy up the shares they are selling overvalued thereby driving the price down.

One user told me that she bought in at $7 and was down $1100 by Monday afternoon. That is the game. Buy the news, sell the hype. Too many bought the hype aka the run up not realizing a swift fall was coming.

After being burned this way on a number of occasions, I offered up a suggestion on the podcast. I recommended a put option play banking that what happened was indeed going to happen. And it did! By close of business Monday my put option was up over 80%. I’m at work with multiple browser tabs open and one of the tabs was glued to the price of MARK as it fell. I eventually took my profits on that option play Wednesday being up 115%. It felt good being able to read the play… and with time and experience (losses) you will be able to do so too.

Funny thing is that Friday people were claiming that MARK was going to run up again on Friday claiming that the stock goes up on Fridays and ebbs on Mondays. Hype. Malarkey like Uncle Joe Biden says. I was skeptical of this but again I kept a close watch. It closed the day just over $2… about 2.04-05. So much for that run up lol. I will acknowledge that today it is trading at 2.11 so there was some gain but hardly enough to appease anyone who jumped in Monday morning above $5. 

Anyway, I’m done watching MARK. On to the next mark no pun intended. Well maybe a little intended. Interested in what I have my eyes set on for this week? Subscribe to the podcast and get your notifications first on what the next play is going to be.

Happy trading bros nation.

Remark Holdings Inc (MARK) stock is trading at $2.86, a gain of $0.69 on high volume. Remark Holdings Inc delivers an integrated suite of AI solutions that enable businesses and organizations to solve problems, reduce risk and deliver positive outcomes. The company's easy-to-install AI products are being rolled out in a range of applications within the retail, financial, public safety, and workplace arenas. The company also owns and operates digital media properties that deliver relevant content and e-commerce solutions. The group operates in one segment namely Technology & Data Intelligence segment which provides products and services to customers based upon the data collected and processed by its proprietary data intelligence software. So what is pushing MARK?

Welcome to Money Talk Sundayz. I’m your investment bro Stevie Bee. Go ahead and drop a like on the video. Let’s talk MARK.

Redditors are currently pushing MARK as the play for Monday. During after hours it is currently sitting at 2.86 a share. There is the real possibility of it going up further. What’s bananas though is that on Friday it opened at 0.91 and ran as high as 2.45 before closing at 2.17. As of this recording like I mentioned it is sitting at 2.86.

Here is the conundrum many who are not already invested in it are debating, does it have more room to grow or is it going to run out of steam and begin to dip? We saw the dip on Friday after a meteoric rise but again over the weekend we saw MARK surge once more. Those who believe it still has room to grow will jump in first thing Monday morning and hope that the wave continues throughout the day.

Skeptics will note the rise and like the mantra says, after every rise comes a fall.

What do we here at Money Talk Sundayz think? The market can go either way. We don’t know what’s going on behind closed doors. We are not aware of any back channel deals that are being made. We can only go off what is made publicly available to us and use that information to make an educated or emotional guess as to the direction this stock will take.

But what if you could have it both ways? What if you could bet on a rise and a fall and come out with a bag still?

Going back to the heart of this podcast, this is the play that I’m considering for MARK. Remember, the heart of this podcast is cataloging, documenting, sharing the plays the Investment Bros make on our marathon to 100K.

With that being said, this is what I’m looking to do.

First off, I don’t want to miss out on an opportunity to swing this stock for some profit so I’m putting in an order to purchase 100 shares. Considering its at 2.86 as of this broadcast, if it goes up $1-2 over the next 48 hours I’m a happy camper and sell off before the inevitable decline in share price of MARK. This in fact is my FOMO play.

Now let’s say it doesn’t go the way expected in the first play. Part 2 of this play is buying a put option with a November 19thexpiration (since that was the earliest available expiration offered when I tried). I buy one put option contract and if MARK craters from the over hype again and I’m a happy camper.

On a side note, lets say MARK goes up on Monday and continues its ride for a couple days next week and begins to fall the week after, I get to have my cake and eat it too. I make my profits off the short swing (if I sell in time) and then also get to cash in on the fall with the put option. I’m hedging my bets you can say. Regardless of whatever play I decide or you decide I can agree it’s too late to jump in on this stock for a long swing. I learned that the hard way with BTX. I bought in at 12. It ran up to 30. I didn’t sell. Now it’s sitting around 9. I’m sitting on a loss but a part of me is refusing to sell at a loss and want to recoup at the least what I put in.